Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth


June 14, 2006
24 Pages - SKU: DECR1305277
License type:
Table of Contents Related Reports
Contents Introduction
Overview of Chronic Lymphocytic Leukemia
Disease Characteristics
Etiology and Pathophysiology
Symptoms
Staging and Survival
Epidemiology
Role of Biological Markers in Prognosis
Current Treatment Options for Chronic Lymphocytic Leukemia
Treatment Decisions
First-Line Therapies
Second-Line Therapies
Third-Line Therapies
Emerging Therapies for Chronic Lymphocytic Leukemia
Monoclonal Antibodies
Rituximab
Lumiliximab
Other Monoclonal Antibodies
Immunotoxins
Cell-Cycle Inhibitors
Antisense Oligonucleotides
Market Outlook
Table 1 Common Staging Systems Used in the Treatment of CLL
Table 2 Select Current Therapies Used for the Treatment of CLL, 2006
Table 3 NCI Definition of Response to Treatment in CLL Patients
Table 4 Select Emerging Therapies for the Treatment of CLL in the United States, 2006
Figure 1 Treatment Algorithm for Chronic Lymphocytic Leukemia
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Oncology/Hematology Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!